Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

(FENCF)

(FENCF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

PO BOX 13628 68 TW ALEXANDER DRIVE DURHAM NC 27709 USA

www.fennecpharma.com P: 919-636-4530

Description:

Adherex Technologies Inc., was incorporated under the Canada Business Corporations Act in September 1996. It is a biopharmaceutical company focused on cancer therapeutics. Its clinical product portfolio includes eniluracil and sodium thiosulfate. Eniluracil is an irreversible inhibitor of DPD, the enzyme primarily responsible for the rapid breakdown of 5-FU in the body. Eniluracil is being developed by the Company to improve the therapeutic value of 5-FU by making it more effective in cancers while reducing the debilitating side effects. Sodium Thiosulfate (STS) is currently marketed for use in humans as part of a treatment for cyanide poisoning. The Company has licensed from Oregon Health & Science University intellectual property rights for the use of STS as a chemoprotectant and are developing STS as a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children. Preclinical and clinical studies conducted by Oregon Health & Science University and others have indicated that STS can effectively reduce the incidence of hearing loss caused by platinum-based anti-cancer agents. It has received Orphan Drug Designation in the United States for the use of STS in the prevention of platinum-induced ototoxicity in pediatric patients. The Company is subject to federal, state, local and foreign laws and regulations governing the use, manufacture, storage, handling and disposal of such materials and certain waste products.

Key Statistics

Overview:

Market Capitalization, $K 138,768
Shares Outstanding, K 15,680
Annual Sales, $ 0 K
Annual Net Income, $ -2,790 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,600 K
60-Month Beta -0.12
% of Insider Shareholders 10.70%
% of Institutional Shareholders 0.00%

Growth:

1-Year Return 0.00%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 08/11/17
Earnings Per Share ttm -0.29
EPS Growth vs. Prev Qtr -83.33%
EPS Growth vs. Prev Year -83.33%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-3 on 09/09/14

FENCF Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -79.70%
Return-on-Assets % -73.35%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 14.28
Book Value/Share 0.62
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar